Mr. Inas Said reports

RISE NANO OPTICS ANNOUNCES FRANKFURT STOCK EXCHANGE LISTING

Rise Nano Optics Ltd.'s common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol U9Y.

The Frankfurt Stock Exchange is one of the world's largest and most established trading platforms, providing access to a broad base of institutional and retail investors across Europe. The listing represents a strategic milestone for Rise as it expands its presence in international capital markets and increases visibility among European investors.

"Listing on the Frankfurt Stock Exchange is an important step in Rise's global capital markets strategy," said Inas Said, founder and chief executive officer of Rise Nano Optics. "As we continue to scale commercialization of our patented Spectraguard technology, expanding access to European investors strengthens our ability to build awareness, drive liquidity and support long-term growth."

Rise recently initiated its U.S. commercialization strategy following regulatory progress and continues to execute a multichannel go-to-market approach targeting optical labs, lens manufacturers, eye care professionals and eyewear brands.

Spectraguard is engineered using proprietary nanoparticle lens architecture designed to selectively filter high-energy visible light between 400 and 600 nanometres, including blue light, while preserving natural colour accuracy and visual clarity. By extending protection beyond traditional ultraviolet-only eyewear, the technology is positioned to address increasing global demand for solutions targeting digital eye strain, light sensitivity and long-term vision stress.

Engages German marketing services

The company has engaged Dr. Reuter Investor Relations GmbH, an arm's-length investor relations and financial public relations firm based in Frankfurt, Germany, to provide investor relations and corporate communications services targeting European capital markets. Pursuant to the agreement, effective Aug. 15, 2026, Dr. Reuter will provide services including the translation and distribution of news releases, editorial content, media outreach, investor communications, social media support, and performance reporting. The initial term of the agreement is six months, ending Feb. 15, 2027, and may thereafter be terminated by either party upon one month of written notice. In consideration for the services, the company will pay Dr. Reuter a cash fee of 6,000 euros per month. Additional fees may be payable for investor road shows and conferences if requested by the company. No stock options or other securities have been granted to Dr. Reuter in connection with the engagement. To the knowledge of the company, Dr. Reuter and its principals do not own any securities of the company and have no present intention to acquire such securities. Dr. Reuter's engagement is intended to increase awareness of the company and its business among the European investment community and does not include the provision of investment advice or market-making services. Dr. Reuter's business address is Tower 185, Friedrich Ebert Anlage 35-37, 60327, Frankfurt, Germany, and the firm may be contacted at e.reuter@dr.reuter.eu and at 49-69-1532-5857.

About Rise Nano Optics Ltd.

Rise Nano Optics is a health technology company specializing in advanced nanotechnology lens solutions designed to selectively filter high-energy visible light wavelengths. Its patented Spectraguard technology integrates nanomaterial innovation, ophthalmic research and scalable optical engineering to serve both clinical and consumer eyewear markets globally.

We seek Safe Harbor.